BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...the amount of active substance in circulation. TMX-201 is under investigation as a vaccine adjuvant. TMX-202...
BioCentury | Jul 18, 2013
Distillery Therapeutics

Indication: Cancer

...agonist TMX-102 is in Phase II testing to treat bladder cancer. The company's TLR7 agonist TMX-202...
BioCentury | Jun 11, 2012
Company News

Foamix, Telormedix deal

...at developing new topical treatments for skin cancer based on a foam formulation of Telormedix's TMX-202...
...for skin cancer, actinic keratosis and genital warts by combining the target-specific binding properties of TMX-202...
...also includes academic partners Charite - Universitatsmedizin Berlin and the German Cancer Research Center . TMX-202...
Items per page:
1 - 3 of 3